Vanguard Group Inc Keros Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,757,120 shares of KROS stock, worth $105 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,757,120
Previous 1,545,758
13.67%
Holding current value
$105 Million
Previous $102 Million
21.53%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding KROS
# of Institutions
156Shares Held
27.5MCall Options Held
28.7KPut Options Held
1.8K-
Black Rock Inc. New York, NY2.51MShares$150 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.6MShares$95.4 Million0.12% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.53MShares$91 Million8.43% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.27MShares$75.7 Million1.4% of portfolio
-
State Street Corp Boston, MA1.22MShares$72.8 Million0.0% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.54B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...